UnivTrevesV1, Main, Exploration, bibRecordById, ISTEX:2D0503325A4D3C658F722C331719FB85571CE860

Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia

Identifieur interne : 001895 ( Main/Exploration ); précédent : 001894; suivant : 001896

Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia

Auteurs : A. Waladkhani [Allemagne]

Source :

European Journal of Cancer Care [ 0961-5423 ] ; 2004-09.

RBID : ISTEX:2D0503325A4D3C658F722C331719FB85571CE860

English descriptors

KwdEn :
- Antineoplastic Agents (adverse effects), Clinical Trials as Topic, Filgrastim, Granulocyte Colony-Stimulating Factor (analogs & derivatives), Granulocyte Colony-Stimulating Factor (therapeutic use), Hematologic Agents (therapeutic use), Humans, Neoplasms (complications), Neoplasms (drug therapy), Neutropenia (chemically induced), Neutropenia (drug therapy), Neutropenia (prevention & control), Recombinant Proteins, Treatment Outcome, chemotherapy, filgrastim, granulocyte colony‐stimulating factors, neutropenia, pegfilgrastim.
MESH :
- chemical , adverse effects : Antineoplastic Agents.
- chemical , analogs & derivatives : Granulocyte Colony-Stimulating Factor.
- chemical , therapeutic use : Granulocyte Colony-Stimulating Factor, Hematologic Agents.
- chemically induced : Neutropenia.
- complications : Neoplasms.
- drug therapy : Neoplasms, Neutropenia.
- prevention & control : Neutropenia.
- Clinical Trials as Topic, Filgrastim, Humans, Recombinant Proteins, Treatment Outcome.

Abstract

Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.

Url:

https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/pdf

DOI: 10.1111/j.1365-2354.2004.00503.x

Affiliations:

Allemagne

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title>
<author><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2D0503325A4D3C658F722C331719FB85571CE860</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1111/j.1365-2354.2004.00503.x</idno>
<idno type="url">https://api.istex.fr/document/2D0503325A4D3C658F722C331719FB85571CE860/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001718</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001718</idno>
<idno type="wicri:Area/Istex/Curation">001604</idno>
<idno type="wicri:Area/Istex/Checkpoint">000965</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000965</idno>
<idno type="wicri:doubleKey">0961-5423:2004:Waladkhani A:pegfilgrastim:a:recent</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15305906</idno>
<idno type="wicri:Area/PubMed/Corpus">000735</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000735</idno>
<idno type="wicri:Area/PubMed/Curation">000735</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000735</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000735</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000735</idno>
<idno type="wicri:Area/Ncbi/Merge">000168</idno>
<idno type="wicri:Area/Ncbi/Curation">000168</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000168</idno>
<idno type="wicri:doubleKey">0961-5423:2004:Waladkhani A:pegfilgrastim:a:recent</idno>
<idno type="wicri:Area/Main/Merge">001A86</idno>
<idno type="wicri:Area/Main/Curation">001895</idno>
<idno type="wicri:Area/Main/Exploration">001895</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia</title>
<author><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier</wicri:regionArea>
<wicri:noRegion>Trier</wicri:noRegion>
<wicri:noRegion>Trier</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Cancer Care</title>
<idno type="ISSN">0961-5423</idno>
<idno type="eISSN">1365-2354</idno>
<imprint><publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2004-09">2004-09</date>
<biblScope unit="volume">13</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="371">371</biblScope>
<biblScope unit="page" to="379">379</biblScope>
</imprint>
<idno type="ISSN">0961-5423</idno>
</series>
<idno type="istex">2D0503325A4D3C658F722C331719FB85571CE860</idno>
<idno type="DOI">10.1111/j.1365-2354.2004.00503.x</idno>
<idno type="ArticleID">ECC503</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0961-5423</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term>
<term>Clinical Trials as Topic</term>
<term>Filgrastim</term>
<term>Granulocyte Colony-Stimulating Factor (analogs & derivatives)</term>
<term>Granulocyte Colony-Stimulating Factor (therapeutic use)</term>
<term>Hematologic Agents (therapeutic use)</term>
<term>Humans</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (drug therapy)</term>
<term>Neutropenia (chemically induced)</term>
<term>Neutropenia (drug therapy)</term>
<term>Neutropenia (prevention & control)</term>
<term>Recombinant Proteins</term>
<term>Treatment Outcome</term>
<term>chemotherapy</term>
<term>filgrastim</term>
<term>granulocyte colony‐stimulating factors</term>
<term>neutropenia</term>
<term>pegfilgrastim</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term>
<term>Hematologic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term>
<term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neutropenia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Filgrastim</term>
<term>Humans</term>
<term>Recombinant Proteins</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chemotherapy‐induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy‐induced neutropenia can result in febrile neutropenia and potentially life‐threatening infections requiring hospitalization and intravenous anti‐infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy‐induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony‐stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy‐induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy‐induced neutropenia as the longer serum half‐life allows once‐per‐chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well‐tolerated option for the management of chemotherapy‐induced neutropenia in patients with cancer.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
</noRegion>
<name sortKey="Waladkhani, A" sort="Waladkhani, A" uniqKey="Waladkhani A" first="A." last="Waladkhani">A. Waladkhani</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001895 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001895 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Rhénanie
   |area=    UnivTrevesV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:2D0503325A4D3C658F722C331719FB85571CE860
   |texte=   Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Jul 22 16:29:01 2017. Site generation: Wed Feb 28 14:55:37 2024

Serveur d'exploration sur l'Université de Trèves

Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia

Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy‐induced neutropenia

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur l'Université de Trèves
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.